CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 113 enrolled
Drug / intervention
APL-130277 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03391882
NCT03391882Phase 3Completed
CompareCT.gov

An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations

Sumitomo Pharma America, Inc.·interventional·Posted Jan 5, 2018·Updated Dec 16, 2022

In Brief

A Phase 3 clinical trial evaluating APL-130277 and subcutaneous apomorphine for Motor OFF Episodes Associated With Parkinson's Disease. Completed, enrolled 113 participants across 31 sites in 6 countries.

Detailed Summary

A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMotor OFF Episodes Associated With Parkinson's Disease
CountriesAustria, France, Germany, Italy, Spain, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 5, 2018
Enrollment StartDec 19, 2018
Primary CompletionAug 11, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.5 years ago

Interventions

APL-130277drug

APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A

subcutaneous apomorphinedrug

subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A